These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 26873817)

  • 1. How the knowledge of fracture risk might influence adherence to oral therapy of osteoporosis in Italy: the ADEOST study.
    Gonnelli S; Caffarelli C; Rossi S; Di Munno O; Malavolta N; Isaia G; Muratore M; D'Avola G; Gatto S; Minisola G; Nuti R
    Aging Clin Exp Res; 2016 Jun; 28(3):459-68. PubMed ID: 26873817
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Persistence, adherence, and medication-taking behavior in women with postmenopausal osteoporosis receiving denosumab in routine practice in Germany, Austria, Greece, and Belgium: 12-month results from a European non-interventional study.
    Hadji P; Papaioannou N; Gielen E; Feudjo Tepie M; Zhang E; Frieling I; Geusens P; Makras P; Resch H; Möller G; Kalouche-Khalil L; Fahrleitner-Pammer A
    Osteoporos Int; 2015 Oct; 26(10):2479-89. PubMed ID: 26018090
    [TBL] [Abstract][Full Text] [Related]  

  • 3. GRAND: the German retrospective cohort analysis on compliance and persistence and the associated risk of fractures in osteoporotic women treated with oral bisphosphonates.
    Hadji P; Claus V; Ziller V; Intorcia M; Kostev K; Steinle T
    Osteoporos Int; 2012 Jan; 23(1):223-31. PubMed ID: 21308365
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improving adherence to and persistence with oral therapy of osteoporosis.
    Bianchi ML; Duca P; Vai S; Guglielmi G; Viti R; Battista C; Scillitani A; Muscarella S; Luisetto G; Camozzi V; Nuti R; Caffarelli C; Gonnelli S; Albanese C; De Tullio V; Isaia G; D'Amelio P; Broggi F; Croci M
    Osteoporos Int; 2015 May; 26(5):1629-38. PubMed ID: 25619634
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Retrospective evaluation of persistence in osteoporosis therapy with oral bisphosphonates in Italy: the TOBI study.
    Gonnelli S; Caffarelli C; Letizia Mauro G; Di Munno O; Malavolta N; Migliaccio S; Nuti R
    Aging Clin Exp Res; 2019 Nov; 31(11):1541-1547. PubMed ID: 31030419
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationship between compliance and persistence with osteoporosis medications and fracture risk in primary health care in France: a retrospective case-control analysis.
    Cotté FE; Mercier F; De Pouvourville G
    Clin Ther; 2008 Dec; 30(12):2410-22. PubMed ID: 19167600
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Persistence at 12 months with denosumab in postmenopausal women with osteoporosis: interim results from a prospective observational study.
    Silverman SL; Siris E; Kendler DL; Belazi D; Brown JP; Gold DT; Lewiecki EM; Papaioannou A; Simonelli C; Ferreira I; Balasubramanian A; Dakin P; Ho P; Siddhanti S; Stolshek B; Recknor C
    Osteoporos Int; 2015 Jan; 26(1):361-72. PubMed ID: 25236877
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Compliance and persistence with oral bisphosphonates for the treatment of osteoporosis in female patients with rheumatoid arthritis.
    Park JH; Park EK; Koo DW; Lee S; Lee SH; Kim GT; Lee SG
    BMC Musculoskelet Disord; 2017 Apr; 18(1):152. PubMed ID: 28399834
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Factors associated with high 24-month persistence with denosumab: results of a real-world, non-interventional study of women with postmenopausal osteoporosis in Germany, Austria, Greece, and Belgium.
    Fahrleitner-Pammer A; Papaioannou N; Gielen E; Feudjo Tepie M; Toffis C; Frieling I; Geusens P; Makras P; Boschitsch E; Callens J; Anastasilakis AD; Niedhart C; Resch H; Kalouche-Khalil L; Hadji P
    Arch Osteoporos; 2017 Dec; 12(1):58. PubMed ID: 28643265
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Persistence with denosumab therapy in women affected by osteoporosis with fragility fractures: a multicenter observational real practice study in Italy.
    Migliaccio S; Francomano D; Romagnoli E; Marocco C; Fornari R; Resmini G; Buffa A; Di Pietro G; Corvaglia S; Gimigliano F; Moretti A; de Sire A; Malavolta N; Lenzi A; Greco EA; Iolascon G
    J Endocrinol Invest; 2017 Dec; 40(12):1321-1326. PubMed ID: 28589380
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased treatment persistence and its determinants in women with osteoporosis with prior fracture compared to those without fracture.
    Jacob L; Dreher M; Kostev K; Hadji P
    Osteoporos Int; 2016 Mar; 27(3):963-969. PubMed ID: 26519418
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Post-fracture pharmacotherapy for women with osteoporotic fracture: analysis of a managed care population in the USA.
    Wilk A; Sajjan S; Modi A; Fan CP; Mavros P
    Osteoporos Int; 2014 Dec; 25(12):2777-86. PubMed ID: 25112720
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Persistence and compliance to osteoporosis therapy in a fracture liaison service: a prospective cohort study.
    Senay A; Fernandes JC; Delisle J; Morin SN; Perreault S
    Arch Osteoporos; 2019 Aug; 14(1):87. PubMed ID: 31375983
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Medical specialty-related adherence to anti-osteoporotic regimens in fragility hip fracture patients.
    Hsu CY; Chiu WC; Chen JF; Chou CL; Su YJ; Yu SF; Cheng TT
    J Bone Miner Metab; 2015 Sep; 33(5):577-83. PubMed ID: 25240801
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term persistence with anti-osteoporosis drugs after fracture.
    Klop C; Welsing PM; Elders PJ; Overbeek JA; Souverein PC; Burden AM; van Onzenoort HA; Leufkens HG; Bijlsma JW; de Vries F
    Osteoporos Int; 2015 Jun; 26(6):1831-40. PubMed ID: 25822104
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Poor bisphosphonate adherence for treatment of osteoporosis increases fracture risk: systematic review and meta-analysis.
    Imaz I; Zegarra P; González-Enríquez J; Rubio B; Alcazar R; Amate JM
    Osteoporos Int; 2010 Nov; 21(11):1943-51. PubMed ID: 19967338
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Compliance and persistence to oral bisphosphonate therapy following initiation within a secondary fracture prevention program: a randomised controlled trial of specialist vs. non-specialist management.
    Ganda K; Schaffer A; Pearson S; Seibel MJ
    Osteoporos Int; 2014 Apr; 25(4):1345-55. PubMed ID: 24445732
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Retrospective Longitudinal Database Study of Persistence and Compliance with Treatment of Osteoporosis in Hungary.
    Lakatos P; Takács I; Marton I; Tóth E; Zoltan C; Lang Z; Psachoulia E; Intorcia M
    Calcif Tissue Int; 2016 Mar; 98(3):215-25. PubMed ID: 26686694
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of medication attitudes with non-persistence and non-compliance with medication to prevent fractures.
    Schousboe JT; Dowd BE; Davison ML; Kane RL
    Osteoporos Int; 2010 Nov; 21(11):1899-909. PubMed ID: 19967337
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A dedicated Fracture Liaison Service telephone program and use of bone turnover markers for evaluating 1-year persistence with oral bisphosphonates.
    van den Berg P; van Haard PMM; van der Veer E; Geusens PP; van den Bergh JP; Schweitzer DH
    Osteoporos Int; 2018 Apr; 29(4):813-824. PubMed ID: 29260291
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.